71 citations
,
May 2006 in “The journal of investigative dermatology/Journal of investigative dermatology”
In this study, researchers found that trichothiodystrophy hair brittleness is linked to abnormalities in sulfur content and structural organization, making it prone to breakage.
This article reviews the clinical and diagnostic features of hairshaft disorders, emphasizing the role of structured patient assessments and the avoidance of hair trauma, but reports no new results.
49 citations
,
January 2003 in “American Journal of Clinical Dermatology”
This review discusses various pediatric hair loss conditions and treatments, highlighting the importance of a holistic approach and noting that no single treatment is universally effective.
Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Hair regrowth on wounded and bald skin may be possible by activating the sonic hedgehog gene, leading to hair regrowth in mice. The findings are promising but may not directly apply to humans.
Curved hair transplantation requires specialized tools and techniques to avoid damaging hair follicles, with modified FUE being the preferred method. Proper extraction and implantation angles are crucial to prevent complications like keloids and sterile folliculitis.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.